Anixa Biosciences Inc. Stock
?
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Anixa Biosciences Inc.
sharewise wants to provide you with the best news and tools for Anixa Biosciences Inc., so we directly link to the best financial data sources.
Financials
News
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
SAN JOSE, Calif., December 15, 2025 -- Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose
Results Support Advancement of the Program into Phase 2 Development
Combination of Keytruda® and the vaccine generated T
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
SAN JOSE, Calif., December 10, 2025 – Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future
Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine
Expands global intellectual property coverage in markets with high breast cancer incidence
New
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
SAN JOSE, Calif., July 9, 2025 -- Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose
SAN JOSE, Calif., June 23, 2025 -- Anixa Biosciences, Inc. (“Anixa” or the “Company”)
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
SAN JOSE, Calif., June 20, 2025 – Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced